Table 6.
Multivariable Logistic Regression Examining Predictors of Failure to Achieve Low-Density Lipoprotein Cholesterol Target for Men Receiving Statin Therapy (HIV+ Men Only)
| Univariate | Multivariate (N=170) | |
|---|---|---|
| Age | 0.99 (0.94, 1.05) | 1.03 (0.95, 1.11) |
| Race | ||
| Black (reference) | 1 | 1 |
| Hispanic/other race | 1.47 (0.41, 5.33) | 2.06 (0.31, 13.52) |
| White | 0.50 (0.18, 1.39) | 0.56 (0.14, 2.18) |
| Body mass index category | ||
| <25 mg/kg2 (reference) | 1 | 1 |
| 25–30 | 1.25 (0.54, 2.90) | 1.08 (0.36, 3.21) |
| >30 | 1.00 (0.35, 2.85) | 0.37 (0.07, 2.04) |
| Diabetes | 6.99 (2.76, 17.68) | 9.48 (3.00, 29.95) |
| Current smoking | 2.12 (0.94, 4.77) | 2.32 (0.74, 7.25) |
| Hypertension | 1.02 (0.47, 2.20) | * |
| No medical insurance | 4.16 (0.94, 18.36) | 6.36 (0.74, 54.83) |
| No insurance coverage for medications | 3.00 (0.97, 9.20)) | 1.49 (0.31, 7.14) |
| Family history of premature CHD | 1.73 (0.76, 3.94) | * |
| Statin potency (high vs. low) | 0.70 (0.29, 1.68) | 0.67 (0.21, 2.17) |
| Chronic HCV | ** | ** |
| AST or ALT >80 U/liter | 4.16 (0.94, 18.36) | 8.78 (1.14, 67.77) |
| HIV RNA >50 copies/ml | 0.96 (0.31, 2.98) | 0.53 (0.11, 2.57) |
| CD4 <200 cells/μl | 0.37 (0.07, 1.99) | 0.39 (0.05, 3.39) |
| Current PI use | 0.87 (0.41, 1.85) | * |
| Current EFV use | 0.48 (0.11, 2.14) | * |
| Current PI+EFV use | 1.89 (0.38, 9.55) | * |
| No current PI or EFV use | 1.66 (0.78, 3.56) | * |
| PI use at visit prior to starting statin therapy | 0.64 (0.30, 1.38) | * |
| EFV use at visit prior to starting statin therapy | 0.66 (0.25, 1.69) | * |
| PI+EFV use at visit prior to starting statin therapy | ** | ** |
| No PI or EFV use at visit prior to starting statin therapy | 1.39 (0.63, 3.09) | * |
| Current fibrate use | 1.89 (0.77, 4.60) | * |
*
NS (p>0.10) in univariate.
**
Excluded due to poor model fit.